It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

#### <sup>1</sup>**Integration of pharmacists' knowledge into a predictive model for teicoplanin dose**

#### <sup>2</sup>**planning**

- 
- 4 Tetsuo Matsuzaki<sup>a</sup>, Tsuyoshi Nakai<sup>a,b</sup>, Yoshiaki Kato<sup>a</sup>, Kiyofumi Yamada<sup>a</sup>, and Tetsuya 5 Yagi<sup>c,\*</sup>
- 
- *a* <sup>7</sup>*Hospital Pharmacy, Nagoya University Hospital, Nagoya, Aichi, 466-8560, Japan*
- *b* <sup>8</sup>*Department of Pharmacotherapeutics and Informatics, Fujita Health University School of*
- <sup>9</sup>*Medicine, Toyoake, 470-1192, Japan*
- *c* <sup>10</sup>*Department of Infectious Diseases, Nagoya University Hospital, Nagoya, Aichi, 466-8560,*

<sup>11</sup>*Japan* 

- 13 Running title: A predictive model for teicoplanin dosing
- 
- 15 <sup>\*</sup>Corresponding author: Tetsuya Yagi
- <sup>16</sup>*Department of Infectious Diseases, Nagoya University Hospital, Nagoya, Aichi, 466-8560,*
- <sup>17</sup>*Japan*

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

- <sup>19</sup>E-mail: tyagi@med.nagoya-u.ac.jp
- 20 Phone: +81-52-744-2955
- 21 Fax: +81-52-744-2801

- 23 Word count for the abstract: 250 words
- 24 Word count for the text: 3332 words

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

#### **Abstract**



40 that dose planning by pharmacists dedicated to TDM (hereafter TDM pharmacists) 41 significantly improved early therapeutic target attainment for patients without an intensive 42 care unit or high care unit stay, providing the first evidence that dose planning of

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .



51 Keywords: Machine learning (ML), Teicoplanin, Initial dosing regimen, TDM

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

## **Importance**



It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

#### 65 1. Introduction





It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

<sup>99</sup>(16). This straightforward approach has yielded a predictive model that designs initial 100 dosing regimens akin to those of pharmacists, exemplifying the potential of ML techniques 101 for integrating expert knowledge into the model. 102 In the present study, we aimed to extend this approach to teicoplanin. Using a dataset of 103 dose planning by pharmacists dedicated to TDM practice (hereafter TDM pharmacist), we 104 trained ML to predict the TDM pharmacists' initial dose planning of teicoplanin. This 105 approach achieved a predictive model that was comparable to that of TDM pharmacists for 106 target trough attainment. In addition, the target attainment rate of patients without TDM 107 pharmacists' dose planning would significantly increase by applying ML. Our study <sup>108</sup>highlights the clinical significance of integrating pharmacist knowledge into predictive 109 models using ML techniques.

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

#### <sup>111</sup>**2. Results**

## <sup>113</sup>**2.1 Patients' characteristics**

<sup>114</sup>We enrolled patients who received teicoplanin between August 2019 and April 2022 at <sup>115</sup>Nagoya University Hospital. During the study period, 1165 patients received teicoplanin 116 treatment. Of these, 751 patients were excluded because of the following reasons: age  $\langle 18 \rangle$ 117 years (n = 546), undergoing peritoneal dialysis or hemodialysis (n = 109), receiving TDM 118 pharmacists' intervention after the initial dose  $(n = 33)$ , resuming teicoplanin treatment 119 within 7 days (n = 31), on extracorporeal membrane oxygenation (ECMO) (n = 16), 120 missing data (n = 9), patient immobility (n = 6), or receiving a single dose for surgical 121 prophylaxis ( $n = 1$ ). The remaining 414 patients were divided into two groups based on 122 whether they received TDM pharmacist intervention (intervention group) or not <sup>123</sup>(nonintervention group). Consequently, 158 and 256 patients were assigned to the 124 intervention and nonintervention groups, respectively (Figure 1 and Tables S1 and S2). 125

## <sup>126</sup>**2.2 Evaluation of therapeutic drug monitoring pharmacists' dose planning**

<sup>127</sup>We first evaluated the clinical significance of TDM pharmacists' intervention in teicoplanin



It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

145 rate at initial TDM (74.8%  $[86/115]$  in the intervention group vs. 57.9%  $[106/183]$  in the 146 nonintervention group,  $p = 0.004$ ), accompanied by a decrease in subtherapeutic ranges  $147$  (14.8% [17/115] in the intervention group vs. 37.2% [68/183] in the nonintervention group, 148 Table 2 and Tables S3 and S4). However, we observed a large bias in intensive care unit <sup>149</sup>(ICU) and high care unit (HCU) admissions between the two groups (24.3% [28/115] in the 150 intervention group vs. 55.7% [102/183] in the nonintervention group,  $p < 1.0 \times 10^{-6}$ , Table <sup>151</sup>S5). Thus, we performed subgroup analyses and found no significant increase in target 152 attainment in patients with an ICU/HCU stay (60.7% [17/28] in the intervention group vs. 153 57.8% [59/102] in the nonintervention group,  $p = 0.832$ , Table 2). This reflects the 154 difficulty in predicting the pharmacokinetics of ICU/HCU stay, where frequent and 155 dramatic changes in the patients' clinical status are often observed. For patients without an 156 ICU/HCU stay, we found a marked increase in the target attainment rate in the intervention 157 group (79.3% [69/87] in the intervention group vs. 58.0% [47/81] in the nonintervention 158 group,  $p = 0.004$ , Table 2). Because there were systemic differences in baseline 159 characteristics between the two groups, especially creatinine clearance (CL<sub>CR</sub>) ( $p = 0.009$ , <sup>160</sup>Figure S1 and Table 3), we applied propensity score matching to reduce the effects of 161 confounding. The results showed that the increase was also found and remained significant



<sup>178</sup>We divided eligible patients into a training group and a testing group at a 94:24 ratio

<sup>179</sup>(approximately 80:20). Subsequently, the neural network model to predict TDM 180 pharmacists' dose planning was trained on the patients in the training group. The prediction 181 accuracies for the loading and maintenance doses (i.e., identical dosing as TDM 182 pharmacists) were both 100% on the training dataset, indicating that the model learned how <sup>183</sup>TDM pharmacists decide dosing regimens. However, in the testing trial, the model scored 184 significantly lower prediction accuracies of 54.2% and 62.5% for the loading and 185 maintenance doses, respectively (Figure 2A, B, left and Table S9). These results indicate 186 that overfitting occurs, which is most likely attributable to the small datasets (17). Because 187 the current dataset consisted of dose planning by multiple pharmacists, each with varying <sup>188</sup>levels of expertise, possible heterogeneity in dose planning among pharmacists may also 189 have contributed to the decrease in accuracy. Next, we retrospectively analyzed the target 190 attainment by ML dose planning using the Bayesian method (2). The original target 191 attainment rate in the testing group was  $81.0\%$  (17/21). Importantly, the rate was expected 192 to slightly increase when ML was applied (95.3% [20/21], Figure 2C, left and Table 5). We 193 hypothesized that ML complemented the weaknesses of suboptimal TDM pharmacists by <sup>194</sup>learning policies from other pharmacists. Taken together, these results indicate that 195 although dose planning tends to differ from that of TDM pharmacists, ML is competent for

It is made available under a CC-BY-ND 4.0 International license.

196 tailoring teicoplanin dosing as TDM pharmacists.



- 198 the cases without intervention, Table S8) and then analyzed the target attainment by this
- <sup>199</sup>ML. As expected from the poor target achievement (Table 2), ML trained on cases without
- 200 intervention failed to maintain the target attainment of TDM pharmacists. The target
- 201 attainment was estimated to decrease from 81.0% (17/21) to 52.4% (11/21) (Figure 2C,
- 202 right, Table 5, and Tables S9 and S10). This decrease was attributed to the subtherapeutic
- 203 doses of teicoplanin; the incidence of subtherapeutic exposure was estimated to increase
- <sup>204</sup>from 4.8% (1/21) to 47.6% (10/21) (Figure 2B, right, Table 5, and Tables S9 and S10). This
- 205 result mirrors the propensity of non-TDM pharmacists to underdose (Tables 2 and 4).
- 206 Taken together, these results suggest that ML model training with the TDM pharmacists'

207 dataset augments model performance in tailoring the teicoplanin dose.

### <sup>209</sup>**2.4 Evaluation of the ML on the external validation dataset**

210 Finally, we investigated whether ML improved target trough attainment. Toward this end,

- 211 we retrained the ML with whole dataset of TDM pharmacists' dose planning  $(n = 118,$
- 212 Table S7) to improve the prediction. Subsequently, we applied retrained ML to patients in



- 230 planning by ML was accompanied by an incidence of overexposure (e.g., case no. 182,
- 231 Tables S11 and S12). Therefore, ML may increase the risk of adverse effects of teicoplanin,
- 232 such as thrombocytopenia, which is observed when trough concentrations exceed 40 mg/L
- <sup>233</sup>(2, 18, 19).
- <sup>234</sup>Altogether, similar to the dose planning by the TDM pharmacists, the current ML is
- 235 expected to play a role in tailoring dose planning, which contributes to early therapeutic
- 236 exposure and consequently leads to treatment success. The model shown in Figure 3 is
- 237 freely available at https://github.com/Matsuzaki-T/TEIC\_study.git.
- 

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

## **3. Discussion**



254 In this study, we first validated the dose planning for teicoplanin by TDM pharmacists in 255 our hospital (Tables 1, 2, and 4). Compared with vancomycin, evidence that pharmacists'

It is made available under a CC-BY-ND 4.0 International license.

256 intervention improves clinical outcomes of teicoplanin treatment is limited. One study 257 demonstrated that pharmacists' intervention improved the attainment of targeted teicoplanin 258 concentrations (24). However, in this study, target achievement was recorded whenever 259 concentrations reached the therapeutic window during treatment. Therefore, whether 260 pharmacists intervention improved early target attainment was unclear. Although the 261 increase in target attainment rate was limited to patients without an ICU/HCU stay, the 262 current study marks the first time that dose planning of teicoplanin by experienced 263 pharmacists led to the achievement of therapeutic windows accompanied by increased 264 adherence to appropriate blood sampling (Tables 1 and 2). These results, along with similar 265 outcomes reported for vancomycin (20, 21), indicate the clinical significance of 266 pharmacists' (especially pharmacists experienced in TDM) intervention in the treatment of 267 MRSA infection.

268 The feature importance of the current ML was in accordance with the conventionally 269 employed predictive covariates for dosing (Figure 3A)  $(9, 25)$ . The timing of dose planning 270 also played a role in the current ML, indicating that our practice of adjusting dose planning 271 in a time-dependent manner was incorporated into the ML.

272 The prediction accuracy of ML was suboptimal at 54.2% and 62.5% for the loading and



It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .



306 size, thereby lacking external generalizability. Second, the dose planning by TDM



It is made available under a CC-BY-ND 4.0 International license.

#### <sup>321</sup>**4. Materials and methods**

## <sup>323</sup>**4.1 Study participants**

<sup>324</sup>This was a single-center, retrospective, observational study of hospitalized patients who 325 received intravenous teicoplanin between August 2019 and April 2022 at Nagoya <sup>326</sup>University Hospital. TDM pharmacists were defined as pharmacists dedicated to TDM. 327 Patients who commenced teicoplanin treatment with TDM expert-recommended dose 328 regimens during the study period were also included. The exclusion criteria were as  $329$  follows: patients aged  $\langle 18 \rangle$  years; undergoing peritoneal dialysis or hemodialysis (including 330 continuous hemodiafiltration); undergoing ECMO; receiving intervention by experts after 331 the initial dose; restarting teicoplanin treatment within 7 days; who were immobile, which  $332$  indicates decreased muscle mass and may cause overestimation of  $CL_{CR}$ ; with surgical 333 antibiotic prophylaxis; and with missing data on sex, age, BW, BMI, and serum albumin 334 and creatinine levels.

<sup>336</sup>**4.2 Comparison of appropriate blood samplings and trough concentrations between**  <sup>337</sup>**the intervention and nonintervention groups** 

It is made available under a CC-BY-ND 4.0 International license.

<sup>338</sup>Eligible patients with serum teicoplanin concentrations were enrolled to evaluate the dose 339 planning by TDM pharmacists. In this analysis, the patients were divided according to 340 whether they received dose planning by TDM pharmacists. 341 Patients with intervention were excluded if the time of blood sampling was not described, 342 protocol deviation occurred, dosing regimen was changed by TDM pharmacists after the 343 initial dose, or blood samples were collected after the completion of teicoplanin treatment. <sup>344</sup>Because blood samples for monitoring teicoplanin trough concentrations should be 345 collected at least 18 h after the last dose (2), we monitored the timing of blood sampling. In 346 cases where initial TDM was performed at the recommended time (18 h after the last dose), 347 the target trough achievement  $(15–30 \text{ mg/L})$  in the intervention group was compared with 348 that in the nonintervention group. 349 Propensity scores were calculated using logistic modeling, with TDM pharmacists' dose 350 planning as the dependent variable. Independent variables included age, BW, BMI, serum 351 albumin level,  $CL_{CR}$  calculated using the Cockcroft–Gault equation (28), and timing of 352 dose planning, which were used as input variables in ML construction. The patients were 353 matched 1:1 using the nearest-neighbor technique, with a caliper distance limited to 10% of 354 the standard deviation of the pooled propensity scores.

It is made available under a CC-BY-ND 4.0 International license.

#### <sup>355</sup>**4.3 Building of the neural network model**

356 The dataset used in this study included clinical and routine laboratory data, initial dosing 357 regimens, and serum teicoplanin concentration at initial TDM (if measured). Age, BW, BMI,  $358$  serum albumin level, and  $CL_{CR}$  were used as features to predict the initial dosing regimens <sup>359</sup>(loading and maintenance doses). We also used the timing of the dose planning (day of the 360 week [T1–T7] and times of day [T0]) as input variables because TDM pharmacists consider 361 dosing regimens so that initial TDM is performed on weekdays as possible. The dataset (n  $362 = 118$ ) was divided into training and test datasets in a 94:24 ratio (approximately 80:20). 363 Numeric input variables (age, BW, BMI, serum albumin level,  $CL_{CR}$ , and time of day [T0]) 364 in the training data were normalized using the following equation:

$$
x_{k,i,norm} = \frac{x_{k,i} - \mu_k}{\sigma_k}
$$

365 where  $x_{k,i}$  is a value of parameter *k* in sample *i*,  $x_{k,i,norm}$  is a normalized value of 366 parameter *k* in sample *i*,  $\mu_k$  is a mean of parameter *k*, and  $\sigma_k$  is a standard deviation of  $367$  parameter  $k$ .

<sup>368</sup>We applied the same scaling to the input variables in the testing data as in the training data 369 to avoid shifting the distribution of the data. For ICU/HCU stay, the variable takes 1 for 370 ICU/HCU stay and 0 otherwise. On each day of the week, the variables were binarized



We trained the neural network to minimize empirical loss over the training data. In this 385 study, we employed cross-entropy loss as the loss function *L*, which was parameterized by 386 the weight matrices *W1*, *W2*, *b1*, and *b2* (Figure S2):

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

$$
L(W1, W2, b1, b2) = -\frac{1}{N} \sum_{x}^{X} log f(x)
$$

389 where *X* is a matrix of the input variables from each training dataset  $x$ , *N* indicates the 390 number of training data points, and  $f(x)$  indicates the score for the correct class.

<sup>392</sup>We optimized each parameter in the model using stochastic gradient descent with an

393 adaptive learning rate using AdaGrad (32):

$$
h \leftarrow h + \nabla_{\theta} L(W)^{2}
$$

$$
\theta \leftarrow \theta - \frac{\eta}{|h|} \nabla_{\theta} L(W)
$$

394 where  $\theta$  is a parameter of weight matrix and  $\eta$  is a learning rate (in this study, 0.1).

### <sup>396</sup>**4.4 Feature importance analysis**

397 In the training process, the permutation feature importance (Breiman–Cutler importance) 398 was calculated, as described in previous studies (33, 34). In this process, a single feature 399 value was randomly shuffled while keeping the other input variables constant. Subsequently, 400 decreases in the prediction accuracy, which indicates how the feature contributes to the ML

It is made available under a CC-BY-ND 4.0 International license.

401 decision, were collected for each input variable. We repeated this process 20 times to

<sup>402</sup>measure the mean decrease in the prediction accuracy for each feature:

$$
PI_i = \frac{1}{N} \sum_{j=1}^{N} \left( PA_{original} - PA_{i,j} \right)
$$

403 where  $PI_i$  (permutation importance) indicates the permutation importance of feature *i*, N is 404 the number of repetitions (in this study, 20), *PA<sub>original</sub>* indicates the original prediction 405 accuracy, and  $PA_{i,j}$  indicates the prediction accuracy upon shuffling feature *i*.

#### <sup>407</sup>**4.5 Estimation of trough concentration with the regimen using the ML model**

408 Data, including serum teicoplanin concentrations at appropriate time points (18 h after the 409 last dose), were included in this analysis. If the ML dosing regimen by the ML was 410 identical to the original dosing regimen, the measured serum teicoplanin concentration was 411 defined as the trough concentration with the ML dosing regimen. Otherwise, the serum 412 teicoplanin concentration in the ML regimen was estimated using Bayesian estimation 413 under the following assumptions:

<sup>414</sup>(i) If the cumulative number of doses was the same in the original and ML regimens,

415 only the dose was changed.





It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

#### <sup>450</sup>**References**







It is made available under a CC-BY-ND 4.0 International license.

501 perspective. NPJ Digit Med 2:69.

- <sup>502</sup>13. Imai S, Takekuma Y, Miyai T, Sugawara M. 2020. A new algorithm optimized for <sup>503</sup>initial dose settings of vancomycin using machine learning. Biol Pharm Bull <sup>504</sup>43:188–193.
- <sup>505</sup>14. Miyai T, Imai S, Yoshimura E, Kashiwagi H, Sato Y, Ueno H, Takekuma Y, 506 Sugawara M. 2022. Machine learning-based model for estimating vancomycin 507 maintenance dose to target the area under the concentration curve of 400–600 <sup>508</sup>mg·h/L in Japanese patients. Biol Pharm Bull 45:1332–1339.
- <sup>509</sup>15. Stefan Schaal. 1999. Is imitation learning the route to humanoid robots? Trends
- 510 Cogn Sci 3:233–242.
- 511 16. Matsuzaki T, Kato Y, Mizoguchi H, Yamada K. 2022. A machine learning model that
- <sup>512</sup>emulates experts' decision making in vancomycin initial dose planning. J Pharmacol
- 513 Sci 148:358–363.
- <sup>514</sup>17. D'souza RN, Huang PY, Yeh FC. 2020. Structural analysis and optimization of 515 convolutional neural networks with a small sample size. Sci Rep 10:834.
- 516 18. Wilson APR. 1997. Safety. In: Teicoplanin; The First Decade. Abingdon, UK, The
- 517 Medicine Group (Education) Ltd.; 134–144.





It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .



It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

561 **Figure 1.** Flow of case selection in the study.

562



577 pharmacists and ML regimens. Blue line and blue dashed lines indicate regression line and

<sup>576</sup>(bottom) decision. **(B)** Serum concentration at initial blood sampling with non-TDM

It is made available under a [CC-BY-ND 4.0 International license](http://creativecommons.org/licenses/by-nd/4.0/) .

<sup>578</sup>95% confidence interval, respectively. **(C)** Cumulative dose of teicoplanin before initial

579 TDM with non-TDM pharmacists and ML regimens. Line indicates reference line of  $y = x$ .



**Figure 1.** Flow of case selection in the study.



of teicoplanin before initial TDM in TDM pharmacists and ML regimens. (Left) TDM pharmacists vs. ML trained with cases with intervention (TDM pharmacists ML). (Right) TDM pharmacists vs. ML trained with cases without intervention (non-TDM pharmacists ML). Line indicates reference line of y = x.**(C)** Serum concentration at initial blood sampling with TDM pharmacists and ML regimens. (Left) TDM pharmacists vs. ML trained with cases with intervention (TDM pharmacists ML). (Right) TDM pharmacists vs. ML trained with cases without intervention (non-TDM pharmacists ML). Gray area indicates therapeutic windows (15–30 mg/L).







**Figure 3. (A)** Permutation feature importance for loading dose (top) and maintenance dose (bottom) decision. **(B)** Serum concentration at initial blood sampling with non-TDM pharmacists and ML regimens. Blue line and blue dashed lines indicate regression line and 95% confidence interval, respectively. **(C)** Cumulative dose of teicoplanin before initial TDM with non-TDM pharmacists and ML regimens. Line indicates reference line of  $y = x$ .

# Table 1. Blood sampling time



medRxiv preprint doi: [https://doi.org/10.1101/2023.12.14.23299934;](https://doi.org/10.1101/2023.12.14.23299934) this version posted December 17, 2023. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante

# Table2. Target attainment



Abbreviations: ICU, intensive care unit; HCU, high care unit.

medRxiv preprint doi: [https://doi.org/10.1101/2023.12.14.23299934;](https://doi.org/10.1101/2023.12.14.23299934) this version posted December 17, 2023. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante

Table 3. Demographic, clinical, and laboratory characteristics of eligible cases without ICU/HCU admission for TDM analysis



Abbreviations: ICU, intensive care unit; HCU, high care unit; TDM, therapeutic drug monitoring; IQR, interquartile range; BW, body weight; SD, standard deviation; BMI, body mass index; CL<sub>CR</sub>, creatinine clearance; Alb, serum albumin.

<sup>a</sup> Chi-square test.

<sup>b</sup> Mann-Whitney U test.

medRxiv preprint doi: [https://doi.org/10.1101/2023.12.14.23299934;](https://doi.org/10.1101/2023.12.14.23299934) this version posted December 17, 2023. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante

Group Trough (mg/L)	Intervention (%)	Nonintervention (%)	p-value (Chi-square test)
$<$ 15	5(10.4)	16(33.3)	
$15 - 30$	40 (83.3)	29(60.4)	0.013
$>30$	3(6.3)	3(6.3)	

Table 4. Target attainment after propensity score matching (non-ICU/HCU)

Abbreviations: ICU, intensive care unit; HCU, high care unit.

medRxiv preprint doi: [https://doi.org/10.1101/2023.12.14.23299934;](https://doi.org/10.1101/2023.12.14.23299934) this version posted December 17, 2023. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante

Group Trough (mg/L)	TDM pharmacists (%)	ML by TDM pharmacists (%)	ML by non-TDM pharmacists (%)
$<$ 15	1 (4.8)	1(4.8)	10(47.6)
$15 - 30$	17(81.0)	20(95.3)	11(52.4)
$>30$	3(14.3)	0(0.0)	0(0.0)

Table 5. Target attainment (internal validation)

Abbreviations: ML, machine learning.

medRxiv preprint doi: [https://doi.org/10.1101/2023.12.14.23299934;](https://doi.org/10.1101/2023.12.14.23299934) this version posted December 17, 2023. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante

# Table 6. Target attainment (external validation)



Abbreviations: ML, machine learning.

medRxiv preprint doi: [https://doi.org/10.1101/2023.12.14.23299934;](https://doi.org/10.1101/2023.12.14.23299934) this version posted December 17, 2023. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante